Sams-Dodd Frank
Bionomics Europe, Les Algorithmes, rue Jean Sapidus, Parc d'Innovation, 67400 Illkirch, France.
Drug Discov Today. 2006 May;11(9-10):465-72. doi: 10.1016/j.drudis.2006.03.015.
The target-based drug discovery approach has for the past 10-15 years been the dominating drug discovery paradigm. However, within the past few years, the commercial value of novel targets in licensing deals has fallen dramatically, reflecting that the probability of reaching a clinical drug candidate for a novel target is very low. This has naturally led to questions regarding the success of target-based drug discovery and, more importantly, a search for alternatives. This paper evaluates the strengths and limitations of the main drug discovery approaches, and proposes a novel approach that could offer advantages for the identification of disease-modifying treatments.
在过去10到15年里，基于靶点的药物发现方法一直是主导的药物发现模式。然而，在过去几年中，新型靶点在授权交易中的商业价值大幅下降，这反映出针对新型靶点获得临床候选药物的概率非常低。这自然引发了关于基于靶点的药物发现是否成功的问题，更重要的是，促使人们寻找替代方法。本文评估了主要药物发现方法的优势和局限性，并提出了一种可能为确定疾病修饰疗法带来优势的新方法。
